138 related articles for article (PubMed ID: 11561805)
1. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
Abb J
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):319-21. PubMed ID: 12151194
[TBL] [Abstract][Full Text] [Related]
3. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus.
Muñoz Bellido JL; Gutiérrez Zufiaurre MN; Sánchez Hernández FJ; Yagüe Guirao G; Segovia Hernández M; García-Rodríguez JA
Int J Antimicrob Agents; 2002 Jul; 20(1):61-4. PubMed ID: 12127713
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.
Betriu C; Redondo M; Boloix A; Gómez M; Culebras E; Picazo JJ
J Antimicrob Chemother; 2001 Dec; 48(6):911-3. PubMed ID: 11733478
[TBL] [Abstract][Full Text] [Related]
6. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Rodríguez JC; Ruiz M; López M; Royo G
Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
[TBL] [Abstract][Full Text] [Related]
8. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
Al-Nawas B; Shah PM
J Antimicrob Chemother; 1998 Jun; 41(6):655-8. PubMed ID: 9687105
[TBL] [Abstract][Full Text] [Related]
9. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Johnson AP; Warner M; Livermore DM
Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
[TBL] [Abstract][Full Text] [Related]
11. Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong.
Ho PL; Ng TK; Yung RW; Que TL; Yip EK; Tse CW; Yuen KY
J Antimicrob Chemother; 2001 Oct; 48(4):590-2. PubMed ID: 11581246
[No Abstract] [Full Text] [Related]
12. [In vitro activity of linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus].
Pérez L; Alarcón T; Jiménez S; de Las Cuevas MC; López-Brea S
Rev Esp Quimioter; 2001 Mar; 14(1):47-50. PubMed ID: 11376349
[TBL] [Abstract][Full Text] [Related]
13. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
[TBL] [Abstract][Full Text] [Related]
14. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.
Grohs P; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 2003 Jan; 47(1):418-20. PubMed ID: 12499229
[TBL] [Abstract][Full Text] [Related]
15. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
[TBL] [Abstract][Full Text] [Related]
16. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809
[TBL] [Abstract][Full Text] [Related]
17. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
[TBL] [Abstract][Full Text] [Related]
19. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
Schmitz FJ; Fluit AC; Lückefahr M; Engler B; Hofmann B; Verhoef J; Heinz HP; Hadding U; Jones ME
J Antimicrob Chemother; 1998 Dec; 42(6):807-10. PubMed ID: 10052906
[TBL] [Abstract][Full Text] [Related]
20. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Leroi MJ; Siarakas S; Gottlieb T
Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):72-4. PubMed ID: 11913510
[No Abstract] [Full Text] [Related]
[Next] [New Search]
